NASDAQ · TRAX

First Tracks Biotherapeutics, Inc.

$42.03 +$6.51 (+18.33%) 1D Pre-market

Key Metrics

$1.24B
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 9
    The stock moved +56.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 9
  • Jun 4
    The stock moved +18.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 4
  • Jun 3
    From its Apr 29 high, the share price fell 35%.

    Peak close $23.64 on Apr 29; trough close $15.32 on Jun 3. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -35%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.24B
Enterprise value
Shares outstanding34.9M
52-wk range$14.72 – $46.45
Avg volume · 20D710.9K
Net cash
Book value / share$7.38
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About First Tracks Biotherapeutics, Inc.
IPO dateApr 6, 2026
Employees

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio8.74
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$256.29M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings